Your browser doesn't support javascript.
loading
The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges.
Puzo, Christian J; Li, Philippa; Tormey, Christopher A; Siddon, Alexa J.
Afiliação
  • Puzo CJ; Yale School of Medicine, New Haven, CT, US.
  • Li P; Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, US.
  • Tormey CA; Department of Pathology, Yale School of Medicine, New Haven, CT, US.
  • Siddon AJ; Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, US.
Lab Med ; 2024 Sep 20.
Article em En | MEDLINE | ID: mdl-39303673
ABSTRACT

OBJECTIVE:

The aim of this study was to determine the efficacy of plerixafor for hematopoietic stem cell (HSC) mobilization prior to autologous stem cell transplantation (aSCT) for patients with multiple myeloma (MM) and various lymphomas, using an oncologist-guided HSC collection goal and markers of cell viability.

METHODS:

A retrospective chart review of all aSCT patients at Yale New Haven Hospital between 2017 and 2021 who met diagnostic criteria for MM, non-Hodgkin, or Hodgkin lymphoma (n = 382) was undertaken. Logistic regression evaluated plerixafor's effect on meeting the individual's HSC goal. The use of t-tests determined plerixafor's relationship to HSC yield and analysis of variance testing assessed its effect on cell viability.

RESULTS:

Mobilization with granulocyte colony-stimulating factor (G-CSF) and plerixafor (odds ratio [OR] = 0.08; P < .05) relative to G-CSF alone was negatively associated with meeting the individual's HSC goal. Diffuse large B-cell lymphoma in patients mobilized with plerixafor yielded fewer HSCs than those without plerixafor (t = -2.78; P = .03). Mobilization regimen (P = .13) had no association with HSC viability. Mobilization failure with plerixafor was rare but occurred in patients with multiple risk factors, including exposure to several rounds of HSC-affecting chemotherapy.

CONCLUSION:

Plerixafor is effective across multiple diagnoses using an oncologist-driven HSC collection endpoint. Its association with mobilization failure is likely attributable to its use in patients predicted to be poor mobilizers.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article